Europe Bets €20 Million on AI to Transform Heart Disease Care

Cardiovascular disease kills more people in Europe than any other condition, claiming roughly one in every three lives across the continent and costing the European Union an estimated €282 billion each year, a figure that exceeds the EU’s entire annual budget. Despite decades of progress in cardiology, the burden of heart disease remains stubbornly high, with wide inequalities in prevention, diagnosis and treatment between and within countries. Now, a newly launched European flagship initiative hopes to change that trajectory by tackling one of the most persistent obstacles in modern medicine: the slow, fragmented and often opaque journey of artificial intelligence from research laboratory to hospital bedside.

The European Cardiovascular Health Data and AI Network, known as CHAIN, has been launched with €20 million in funding from the EU4Health Programme and is coordinated by the European Society of Cardiology (ESC). The 36-month project brings together a consortium of 53 partners from 20 European countries, spanning universities and research centres, hospitals and clinical networks, technology companies, national ministries of health and patient organisations. Its central ambition is to build a federated ecosystem for the safe, effective and scalable adoption of AI in cardiovascular care, aligned with the European Health Data Space, the EU’s ambitious framework for cross-border health data sharing.

The problem CHAIN seeks to solve is well documented. AI models capable of detecting heart disease earlier, stratifying patient risk more accurately and supporting clinical decisions have proliferated in the scientific literature, yet their uptake in routine care remains patchy and inconsistent. Standardised validation mechanisms are largely lacking, meaning hospitals and health authorities often have no reliable way of knowing which algorithms perform as advertised, for which patient populations, and under which clinical conditions. The result is a landscape in which promising tools stall at the pilot stage while unvetted ones occasionally reach clinics without adequate scrutiny.

CHAIN’s technical answer to this challenge rests on two pillars: a federated data infrastructure and a system of validation credentials. Rather than centralising sensitive patient records, the project will securely connect hospitals, health data hubs and disease registries across Europe in a federated architecture, allowing AI solutions to be tested, validated and deployed at scale while data remain within their originating institutions. This approach, which aligns with the privacy-preserving principles underpinning the European Health Data Space, enables algorithms to be evaluated on diverse, real-world populations drawn from multiple healthcare systems, a critical step for detecting the biases and performance gaps that often emerge when models trained in one setting are applied in another.

The second pillar is a European repository of validated AI solutions, each accompanied by what the project calls an ‘AI passport’. These passports will document a model’s performance, safety and suitability for clinical use, giving healthcare authorities, hospital administrators and practicing clinicians clear, standardised evidence on which solutions work, for whom and in which settings. In an era when clinicians and patients alike are wary of opaque algorithmic tools, the passports are designed to function as a trusted seal of approval, helping decision-makers distinguish genuinely useful innovations from overhyped ones. Professor Folkert Asselbergs of Amsterdam University Medical Centre, CHAIN’s scientific coordinator and chair of the ESC AI Gateway, emphasised that in an era of misinformation, patients and healthcare professionals are looking to medical societies to provide a framework for implementing trusted solutions that add real value beyond what is currently available.

To prove the framework works in practice, CHAIN will implement six real-world use cases across 13 countries, deliberately chosen to cover the full continuum of cardiovascular care. The use cases span risk stratification, early disease detection, clinical decision support and the management of complex cardiovascular conditions, ensuring that the validation and deployment mechanisms are tested across different healthcare settings, from large academic centres to smaller regional hospitals. This breadth matters: an AI tool that performs well in a well-resourced Dutch university hospital may fail in a rural clinic in eastern Europe, and the project’s multi-country design is intended to surface such disparities before tools are scaled.

The initiative does not start from scratch. CHAIN builds on the ESC’s EuroHeart registry network, which already unifies 18 ESC member countries with standardised data on cardiovascular care and outcomes, providing tools that help countries monitor results, compare practices and drive sustainable improvements. It will also seek synergies with a constellation of existing EU projects, including EUCAIM, COMPASS AI, AI4HF, DataTools4Heart, EHDEN, JACARDI, TEHDAS2 and Xt-EHR, an effort to maximise complementarities and avoid duplicating infrastructure that Europe has already invested in. The project is explicitly positioned as a key implementation vehicle for the EU Safe Hearts Plan, in particular its flagship initiative on innovation and integration of AI and digital technologies in cardiovascular healthcare.

Timing is a central theme of the launch. CHAIN arrives just as the European Health Data Space, the EU’s landmark AI Act, and an evolving regulatory framework for medical products, spanning pharmaceutical, medical device and in vitro diagnostic legislation, are reshaping how AI is developed, evaluated and deployed across European healthcare. Navigating this regulatory landscape is one of the project’s implicit challenges: any AI tool validated through CHAIN will need to satisfy not only clinical evidence standards but also the transparency, safety and human-oversight requirements that the AI Act imposes on high-risk medical applications. By building governance, evaluation and scale-up mechanisms into its core design, the consortium hopes to create a template that regulators, industry and health systems can adopt more widely.

The political weight behind the project is considerable. Olivér Várhelyi, the EU Commissioner for Health and Animal Welfare, framed the challenge bluntly, saying the question is no longer simply what AI can do, but how to make it work safely and effectively for patients and health professionals in everyday healthcare, and that this is where CHAIN can make a real difference. Professor Cecilia Linde, President of the ESC and a cardiologist at the Karolinska Institute in Sweden, struck a similar note, arguing that the need to act is critical given that one in three deaths in Europe is caused by cardiovascular disease, and describing CHAIN as an effort to turn the promise of AI into better cardiovascular health for everyone by helping trusted innovations reach patients safely and equitably.

Over the next three years, the consortium hopes to deliver a strategic roadmap for scaling AI adoption in cardiology across Europe, one that Professor Asselbergs says will benefit research and industry through shared infrastructure and standards, while validated decision-support tools help reduce the burden on overstretched healthcare systems. The ultimate measure of success, he argues, will be clinical: trustworthy tools that translate into earlier, more accurate diagnosis and safer, more personalised care for patients. If CHAIN succeeds, it could offer something Europe has lacked so far, a coherent, continent-scale pathway for moving AI in medicine from promising publications to measurable patient impact, and a model that other fields of medicine, from oncology to neurology, may soon seek to replicate.

Subject of Research: A European initiative to validate and scale artificial intelligence for cardiovascular disease prevention, detection and treatment

Article Title: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care

Article References: From promise to patient impact: New European initiative aims to accelerate AI in cardiovascular care. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, cardiovascular disease, CHAIN, European Society of Cardiology, EU4Health, European Health Data Space, AI validation, federated data, clinical decision support, health data infrastructure, AI passports, digital health